Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H1-SWITCH bilastine switching study in chronic spontaneous urticaria
jRCTs051180105Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of bilastine in chronic idiopathic urticaria (CIU) (2 arms), sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoint: Average total symptom score at Days 5-7. Started Jul 2019; status: completed.
02
Drugs
bilastine
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on jRCTs051180105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180105.